.jpg/:/rs=h:100,cg:true,m/qt=q:95)
carboxamil- the Lung cancer drug of the future-today
Transforming biotechnology with cutting-edge innovations.
CRITERIA
Have Local Advanced Stage 3 Lung Cancer
Over 18 years of Age
Previous Scans of lung
Identified tumors in Lung
Quality First
In home care monitored by nurse practitioner with full practice authority in the care of late-stage lung cancer
Expert Care
Our experienced team brings advanced skill, knowledge and utmost passion to every patient.
Real Results
We will explain on a daily basis and bring the patient up to date on the latest results so each patient will feel secure and comfortable in the study.
Our Mission
Carboxamil is for the treatment of local advanced stage 3 lung cancers administered by inhaler in your own home
.Carboxamil(Cromolyn Sodium) is an FDA approved drug repurposed for local advanced stage 3 lung cancers. Carboxamil has an excellent FDA safety profile with no toxicity or side effects There is no hair loss, no compromised immune system or infections from using Carboxamil. Carboxamil has adaptive immunity where tumors will not return to the same place. FDA Expanded Access/ Compassionate Use
Revolutionizing the way Lung cancer is treated
Carboxamil
Carboxamil (Cromolyn Sodium) is a repurposed FDA approved drug that is non-toxic with no known side effects, meaning no hair loss, no compromised immune system, no infections from using Carboxamil
Mode of Action
Carboxamil binds to receptor GPCR 35 and turns off the cancer cascade. By turning off the cancer cascade like your home faucet NEW tumors cannot form, grow or metastasize allowing for the immune system to destroy the tumors that are present
Local target therapy
Carboxamil is delivered directly to the tumor site by a state-or-the-art dry powder inhaler allowing for 100% of Carboxamil drug concentration to destroy the tumors that are present inhibiting tumors from spreading elsewhere. Carboxamil has adaptive immunity where tumor will not return to same place
Biomarkers
Carcinex Inc has developed the most advanced early detection biomarkers for solid tumors cancers. These biomarkers have 95% selectivity. These biomarkers are not present in normal tissue
TEAM FOR LUNG CANCER
CHARLES OWEN-CEO
LANA NESTERENKO- CMO Nurse Practitioner (NP) | RN
BRAD GONANO- COO PharmD, BCSCP
Charles Owen repurposed Carboxamil; for the treatment of local advanced stage lung cancers.
35 years of cancer research
Lab and field research
Animal and human studies
FDA orphan drug designation
2 patents granted
Dedicated life to developing Carboxamil- Lung cancer drug of the future a life
My goal is to build a new oncology ecosystem today-
Nothing is better in life then saving a life
BRAD GONANO- COO PharmD, BCSCP
LANA NESTERENKO- CMO Nurse Practitioner (NP) | RN
BRAD GONANO- COO PharmD, BCSCP
Pharmaceutical scientist and board-certified pharmacist with deep expertise in drug formulation, sterile injectables, large molecule therapeutics, and early stage pharmaceutical development. Proven ability to originate novel formulations from first principles, translate bench-scale concepts into manufacturable dosage forms, and navigate
Pharmaceutical scientist and board-certified pharmacist with deep expertise in drug formulation, sterile injectables, large molecule therapeutics, and early stage pharmaceutical development. Proven ability to originate novel formulations from first principles, translate bench-scale concepts into manufacturable dosage forms, and navigate complex regulatory and quality frameworks. Extensive experience at the intersection of R&D, CMC, sterile manufacturing, and regulatory compliance, with hands-on leadership in cleanroom design, lyophilization, and parenteral drug delivery systems. Recognized for rigorous scientific thinking, technical problem-solving, and the ability to operate independently at a senior level in high-complexity environments.
LANA NESTERENKO- CMO Nurse Practitioner (NP) | RN
LANA NESTERENKO- CMO Nurse Practitioner (NP) | RN
LANA NESTERENKO- CMO Nurse Practitioner (NP) | RN
Licensed AGPC-NP since April 2025 with 17+ years of nursing experience, including 7 years in hospice and geriatric care. Skilled in advanced patient assessment, diagnosis, and treatment, with a proven track record of delivering compassionate, high-quality care. Recognized for strong clinical judgment, excellent communication, and colla
Licensed AGPC-NP since April 2025 with 17+ years of nursing experience, including 7 years in hospice and geriatric care. Skilled in advanced patient assessment, diagnosis, and treatment, with a proven track record of delivering compassionate, high-quality care. Recognized for strong clinical judgment, excellent communication, and collaboration with interdisciplinary teams to achieve optimal patient outcomes